EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

So when my urologist said in 2019 that my PSA test showed the most aggressive form of prostate cancer, I was not prepared. I was 68, and my annual tests had always been normal. Soon I embarked on a ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a ...

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

Bayer said its Nubeqa treatment was approved by the EU for advanced prostate cancer. The German pharmaceutical and agricultural conglomerate said the European Commission granted approval of Nubeqa in ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Investigators compared early oncologic outcomes by staging modality among men diagnosed with very high-risk prostate cancer.

The European Commission has granted marketing authorization in the European Union (EU) for German pharma major Bayer’s Nubeqa ...